Tom Lehrer's guide to design of SARS-CoV-3 main protease inhibitors for treatment of COVID-32
Molecular Design
JANUARY 12, 2021
> It’s been ages since my last COVID-19 post (How not to repurpose a 'drug') and I’ll kick blogging off for 2021 with a follow up to an even older post (SARS-CoV-2 main protease. Crowdsourcing, peptidomimetics and fragments). Pfizer began a phase I study of the SARS-CoV-2 main protease inhibitor PF-00835321 (K i = 0.27
52 
Let's personalize your content